MaxCyte, Inc. (NASDAQ:MXCT) Director Sells $80,161.97 in Stock

MaxCyte, Inc. (NASDAQ:MXCT) Director Stanley C. Erck sold 21,607 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total value of $80,161.97. Following the sale, the director now directly owns 269,118 shares in the company, valued at $998,427.78. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

MaxCyte Stock Up 1.4 %

Shares of MXCT opened at $3.67 on Friday. The company has a market capitalization of $384.70 million, a price-to-earnings ratio of -10.49 and a beta of 1.39. MaxCyte, Inc. has a 52 week low of $2.45 and a 52 week high of $5.55. The stock’s 50-day moving average price is $4.11 and its 200-day moving average price is $4.25.

MaxCyte (NASDAQ:MXCT) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.05. The business had revenue of $10.43 million for the quarter, compared to analyst estimates of $8.20 million. MaxCyte had a negative return on equity of 15.52% and a negative net margin of 77.97%. During the same quarter in the prior year, the firm posted ($0.10) EPS. As a group, equities analysts anticipate that MaxCyte, Inc. will post -0.44 EPS for the current fiscal year.

Institutional Trading of MaxCyte

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MXCT. Russell Investments Group Ltd. acquired a new position in shares of MaxCyte in the first quarter worth about $28,000. PNC Financial Services Group Inc. acquired a new stake in MaxCyte in the fourth quarter valued at approximately $29,000. China Universal Asset Management Co. Ltd. increased its position in shares of MaxCyte by 65.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 19,884 shares of the company’s stock valued at $83,000 after buying an additional 7,898 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of MaxCyte by 20.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company’s stock valued at $106,000 after buying an additional 4,320 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of MaxCyte by 22.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company’s stock worth $128,000 after buying an additional 5,927 shares during the period. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.